Small-molecule switches to control universal CAR T cell therapy
Precision Control of Universal CAR Activity by Small Molecule Adaptors
Small drug-like adaptors are being developed to turn on, target, and fine-tune universal CAR T cells for people with cancers or autoimmune diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11251651 on NIH RePORTER |
What this research studies
This work is creating small, drug-like adaptor molecules that can hook up to a universal SNAP-CAR so the same engineered T cells can be redirected to different disease cells. The team will design chemical switches that only activate the CAR in tissues with specific enzyme activity, aiming to reduce damage to healthy tissue. They will also explore ways to expand the range of targets by chemically creating new markers on diseased cells. Much of the program will be done in the lab and preclinical models at the University of Pittsburgh as a step toward future human testing.
Who could benefit from this research
Good fit: People with cancers or autoimmune diseases that are candidates for cellular immunotherapy or that express targetable cell-surface markers could be the intended future beneficiaries or trial candidates.
Not a fit: Patients whose conditions are not driven by targetable cell-surface antigens or who are ineligible for cell-based therapies are unlikely to benefit in the near term.
Why it matters
Potential benefit: If successful, this approach could make CAR T treatments more precise, safer, easier to manufacture, and useful for solid tumors and autoimmune conditions.
How similar studies have performed: CAR T therapies have been highly successful for some blood cancers, but using small-molecule adaptors to control a universal CAR is a newer, mostly preclinical approach with limited clinical testing so far.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Deiters, Alexander — University of Pittsburgh at Pittsburgh
- Study coordinator: Deiters, Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.